2026-06-30

Artivila Announces Dosing of First Patient in Phase 2 Trial of ARD-885 for RA

SHENZHEN, China, June 30, 2026 - Artivila Biopharma today announced that the first patient has been dosed in its Phase 2 clinical trial of ARD-885, a first-in-class IRAK4/IRAK1 dual inhibitor for the treatment of rheumatoid arthritis (RA).

2026-06-25

Artivila Biopharma Secures Over $12.8M Series A Financing

​SHENZHEN, China, June 25, 2026 -- Artivila Biopharma ("Artivila"), a clinical-stage biotech company pioneering AI-driven drug discovery, today announced the successful closing of a Series A financing of over 13 million USD. The round was led by Green Pin

2025-09-22

Artivila Announces Successful Completion of ARD-885 Phase I Clinical Study

ShengZhen, Sep 22, 2025, Artivila , a clinical stage biopharmaceutical company (“Artivila”), announced the successful completion of a Phase I clinical study of ARD-885, a novel Class 1 small molecule drug developed by the company for the treatment of auto

2024-12-11

Artivila Biopharma Announces Clearances of IND Applications for ARD-885 by China

ShenZhen, Guangdong, China. December 11, 2024- Artivila Biopharma today announced that the Chinese NMPA and the United States FDA have approved its IND applications for its small molecule new drug ARD-885 for the treatment of rheumatoid arthritis.